Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06655441

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

Led by Southern California College of Optometry at Marshall B. Ketchum University · Updated on 2026-05-05

30

Participants Needed

1

Research Sites

56 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this research study is to evaluate the effects of trehalose, an ingredient found in commercially available artificial tears, on the corneal barrier function. The investigators will assess corneal dryness and measure the relative corneal epithelial "barrier" function (the degree to which the cornea can prevent penetration of sodium fluorescein dye into the eye) after using eye drops that contain 3% trehalose for one month.

CONDITIONS

Official Title

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult subjects over 18 years old with moderate-to-severe dry eye, meeting dry eye stages 3 or 4 criteria
  • Normal eyelid position and closure
  • For aqueous tear deficiency, Schirmer I test less than 5.0 mm wetting in 5 minutes without anesthesia
Not Eligible

You will not qualify if you...

  • Eye surgery in either eye within the past 12 months (except LASIK or kerato-refractive surgery if over 12 months ago)
  • Serious eye trauma in either eye within the past 6 months
  • Hypersensitivity to any study medication components
  • History of certain eye infections or diseases (herpes simplex keratitis, vaccinia, varicella, viral, bacterial, mycobacterial, fungal eye diseases)
  • Active ocular allergy
  • Pregnant, nursing, or planning pregnancy females
  • Eyelid deformities worse than mild (ectropion, entropion, ptosis)
  • Use of topical ocular medications during the study
  • Unstable use of systemic steroids, immunosuppressives, or anticholinergic drugs for autoimmune connective tissue disease within 30 days prior
  • Uncontrolled diabetes or peripheral neuropathy
  • Active intraocular inflammation like iritis
  • Wearing rigid gas permeable or scleral contact lenses within 6 months; soft lenses not worn within 1 month prior
  • Use of punctual plugs within 30 days before study start

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Marshall B. Ketchum University

Fullerton, California, United States, 92831

Actively Recruiting

Loading map...

Research Team

S

Shora Ansari, OD, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here